newsfilter
← Latest News
GlobeNewswire·

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received